Monteris™ founded as a technology start-up from research work pioneered at the St. Boniface General Hospital, Winnipeg, Manitoba.
2000
•
Initial “seed funding” received
2003
•
“Proof of concept” prototypes completed.
2005
•
July: Fully operational, integrated prototype system successfully passed evaluation tests.
•
October: The first in vivo tests using swine demonstrated system capability for lesion size, shape and boundary control.
2006
•
In vivo swine studies confirmed system refinements, optimal treatment and imaging parameters, and thermal characteristics of brain tissue.
2007
•
GLP “Preclinical Canine Trial”, demonstrating safety and efficacy in treating subjects with brain tumors.
•
First-use-in-human “Feasibility Trial,” demonstrating capability to safely treat a limited number of humans with advanced glioblastoma multiforme brain tumors.
2008
•
Phase I Clinical Trial, demonstrating safety and efficacy in treating humans with advanced glioblastoma multiforme brain tumors. (TBD)
2009
•
Phase II Clinical Trial, demonstrating safety and efficacy in treating humans with advanced glioblastoma multiforme brain tumors. (TBD)
2010
•
Regulatory approval to market. (TBD)
*The AutoLITT™ System is an investigational device
which has not yet been tested in humans.
Brain Cancer
